Vincere makes new medicines to treat age-related diseases including Parkinson’s and Kidney disease.

Our work is backed by top agencies such as the National Institutes of Health (NIH) and the Michael J Fox Foundation (MJFF) with over $8 million in grant funding.

Expert investors include Draper Associates, Beiersdorf, Daewoong Pharma, HanAll Biopharma, Portal Innovations, Viva, Beresford, Freemind, KreaMedica, Alumni Ventures Group, Healthspan Capital, QuadraScope, LongGame, Kastor, and others.

Our virtual cell platform integrates human genetics, cellular network models, and in-silico biology to identify high-leverage therapeutic targets - prioritizing USP30 early as a powerful driver of mitochondrial repair.